Arrowhead Pharmaceuticals, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-02-02$73.00 RISE2026-03-12$55.01 PEAK2026-05-14$79.69 101d | -24.6% 38d | Missed | Missed | — | — | +44.9% 63d | Missed |
DROP2025-07-09$18.88 RISE2025-07-21$14.71 PEAK2025-10-06$37.50 89d | -22.1% 12d | Missed | Missed | — | — | +154.9% 77d | Missed |
DROP2024-12-02$26.34 RISE2025-04-08$9.99 PEAK2025-06-10$16.97 190d | -62.1% 127d | Missed | Missed | — | — | +69.9% 63d | Missed |
DROP2024-12-02$26.34 RISE2025-01-14$18.05 PEAK2025-01-23$21.53 52d | -31.5% 43d | Missed | Missed | — | — | +19.3% 9d | Missed |
DROP2024-07-25$28.94 RISE2024-11-21$18.28 PEAK2024-12-02$26.34 130d | -36.8% 119d | Missed | Missed | — | — | +44.1% 11d | Missed |
DROP2024-07-16$29.54 RISE2024-10-10$17.70 PEAK2024-12-02$26.34 139d | -40.1% 86d | Missed | Missed | — | — | +48.8% 53d | Missed |
DROP2024-01-08$39.48 RISE2024-04-25$21.87 PEAK2024-07-16$29.54 190d | -44.6% 108d | Missed | Missed | — | — | +35.1% 82d | Missed |
DROP2023-07-27$35.83 RISE2023-11-30$21.20 PEAK2024-01-08$39.48 165d | -40.8% 126d | Missed | Missed | — | — | +86.2% 39d | Missed |
DROP2023-06-28$36.92 RISE2023-10-30$23.22 PEAK2024-01-08$39.48 194d | -37.1% 124d | Missed | Missed | — | — | +70.0% 70d | Missed |
DROP2022-12-30$40.56 RISE2023-03-23$23.68 PEAK2023-05-05$41.38 126d | -41.6% 83d | Missed | Missed | — | — | +74.7% 43d | Missed |
DROP2022-08-15$48.31 RISE2022-11-28$28.00 PEAK2022-12-30$40.56 137d | -42.0% 105d | Missed | Missed | — | — | +44.9% 32d | Missed |
DROP2022-08-15$48.31 RISE2022-09-26$29.63 PEAK2022-10-28$35.87 74d | -38.7% 42d | Missed | Missed | — | — | +21.1% 32d | Missed |
DROP2022-02-09$54.66 RISE2022-06-16$27.79 PEAK2022-08-15$48.31 187d | -49.2% 127d | Missed | Missed | — | — | +73.8% 60d | Missed |
DROP2022-01-03$69.97 RISE2022-05-11$28.95 PEAK2022-08-08$47.02 217d | -58.6% 128d | Missed | Missed | — | — | +62.4% 89d | Missed |
DROP2021-11-08$82.51 RISE2022-03-14$39.62 PEAK2022-04-04$50.61 147d | -52.0% 126d | Missed | Missed | — | — | +27.7% 21d | Missed |
1–15 / 23 1 / 2 | |||||||
PASADENA, Calif., May 27, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity and metabolic dysfunction-associated steatohepatitis (MASH). The data presented at the European Association for the Study of the Liver Congress (EASL 2026) demonstrate that ARO-INHBE treatment led to clinically meaningful r
- Targeting Activin E may represent a novel therapeutic strategy for metabolic dysfunction-associated steatohepatitis (MASH) and obesity‑related metabolic dysfunction- ARO-INHBE produced meaningful reductions in liver
Arrowhead Pharmaceuticals presented new clinical data on plozasiran in patients with moderate to severe renal or hepatic impairment at a major scientific congress. The data focused on efficacy and safety outcomes in these higher risk groups. A separate case report highlighted long term triglyceride reduction with plozasiran use during pregnancy. For investors watching Arrowhead Pharmaceuticals (NasdaqGS:ARWR), these updates come with the stock at $74.95 and 1 year gains of 387.6%. The move...
Arrowhead Pharmaceuticals presented new clinical data on plozasiran in patients with moderate to severe renal or hepatic impairment at a major scientific congress. The data focused on efficacy and safety outcomes in these higher risk groups. A separate case report highlighted long term triglyceride reduction with plozasiran use during pregnancy. For investors watching Arrowhead Pharmaceuticals (NasdaqGS:ARWR), these updates come with the stock at $74.95 and 1 year gains of 387.6%. The move...
PASADENA, Calif., May 26, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented new positive clinical data for plozasiran supporting its use in patients with moderate-to-severe renal impairment or moderate hepatic impairment without the need for dose adjustment, and a case report suggesting that preconception exposure to plozasiran may be associated with sustained lowering of fasting triglyceride (TG) levels through the term of a pregnancy. The data were presented in two oral pres
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the best medical stocks to invest in according to billionaires. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) received a rating update from Bernstein on May 13. The firm lifted the price target on the stock to $46 from $35, maintaining a Market Perform rating on the shares and stating that biotech has had […]
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the best medical stocks to invest in according to billionaires. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) received a rating update from Bernstein on May 13. The firm lifted the price target on the stock to $46 from $35, maintaining a Market Perform rating on the shares and stating that biotech has had […]
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in severe hypertriglyceridemia, during a fireside chat at RBC Capital Markets’ 2026 Global Healthcare Conf
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in severe hypertriglyceridemia, during a fireside chat at RBC Capital Markets’ 2026 Global Healthcare Conf
REDWOOD CITY, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Codexis, a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, shared new advances in RNA therapeutic manufacturing at TIDES USA 2026 at the Hynes Convention Center in Boston. Through presentations and a panel discussion, the Company highlighted how its ECO Synthesis® Manufacturing Platform is advancing the production of siRNA, now enabling stereochemical control while add
Arrowhead Pharmaceuticals, Inc. (ARWR) Bank of America Global Healthcare Conference 2026 May 11, 2026 8:00 PM EDTCompany ParticipantsDr.
Presenter SpeechJason Gerberry We are here with our next company presenter at the BofA Annual Healthcare Conference. My name is Jason Gerberry. I cover Pharma and Biotech here, and I am joined by
Elevated Activin E Levels Correlate with Insulin Resistance and Metabolic Dysfunction in Non-Human Primates and Adult Patients with Obesity and Type 2 Diabetes Jane Kerr1, John...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is moving into a more commercial phase while continuing to expand its RNA interference pipeline, Chief Executive Officer Chris Anzalone said during a presentation with BofA pharma and biotech analyst Jason Gerberry at the BofA Annual Healthcare Conference. An
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is moving into a more commercial phase while continuing to expand its RNA interference pipeline, Chief Executive Officer Chris Anzalone said during a presentation with BofA pharma and biotech analyst Jason Gerberry at the BofA Annual Healthcare Conference. An
Systemic RNAi Targeting MAPT: Advancing Tau Suppression Across the CNS with TRiM SC Kayal Madhivanan, Ph.D., Arrowhead Pharmaceuticals TIDES USA 2026 ...
Bernstein analyst William Pickering maintains Arrowhead Pharma (NASDAQ:ARWR) with a Market Perform and raises the price target from $35 to $46.
Recent performance snapshot Arrowhead Pharmaceuticals (ARWR) has drawn investor attention after its stock moved in recent sessions, with recent returns over the past week, month and past 3 months prompting closer scrutiny of its current valuation and fundamentals. See our latest analysis for Arrowhead Pharmaceuticals. At around $79.04, Arrowhead Pharmaceuticals’ recent 1-month share price return of 21.34% and very large 1-year total shareholder return of 417.28% point to strong momentum,...
Recent performance snapshot Arrowhead Pharmaceuticals (ARWR) has drawn investor attention after its stock moved in recent sessions, with recent returns over the past week, month and past 3 months prompting closer scrutiny of its current valuation and fundamentals. See our latest analysis for Arrowhead Pharmaceuticals. At around $79.04, Arrowhead Pharmaceuticals’ recent 1-month share price return of 21.34% and very large 1-year total shareholder return of 417.28% point to strong momentum,...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ARWR | +4.14% | +21.11% | +17.35% | +384.82% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +1.17% | +26.82% | +20.80% | +372.13% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 7.27M | $455.62M | 0.02% | Added+11.4% | 2026-03-31 |
| StateStreet | passive | 6.50M | $407.31M | 0.01% | Added+1.4% | 2026-03-31 |
| DEShaw | quant | 1.18M | $74.23M | 0.04% | Added+710.5% | 2026-03-31 |
| RenTech | quant | 1.04M | $64.99M | 0.10% | New | 2026-03-31 |
| Bridgewater | macro | 95.6K | $5.99M | 0.03% | Added+59.3% | 2026-03-31 |
| Wellington | fundamental | 54.5K | $3.42M | 0.00% | Added+14.8% | 2026-03-31 |
| TwoSigma | quant | 35.8K | $2.24M | 0.00% | New | 2026-03-31 |
| TRowePrice | fundamental | 1.04M | $65.44K | 0.01% | Added+24.4% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | -1.20 | — | — |
| 2026-05-07 | -1.11 | -0.93 | +15.98% |
| 2026-02-05 | -0.37 | 0.22 | +159.86% |
| 2025-11-25 | -0.16 | -0.18 | -14.45% |
| 2025-08-07 | -1.10 | -1.26 | -14.41% |
| 2025-05-12 | -0.46 | 2.75 | +695.04% |
| 2025-02-10 | -0.72 | -1.39 | -92.16% |
| 2024-11-26 | -0.92 | -1.37 | -48.60% |
| 2024-08-08 | -0.59 | -1.38 | -134.53% |
| 2024-05-09 | -0.20 | -1.02 | -422.76% |
| 2024-02-06 | -0.83 | -1.24 | -50.26% |
| 2023-11-29 | -0.58 | -1.02 | -76.41% |
| 2023-08-07 | -0.53 | -0.96 | -81.83% |
| 2023-05-02 | -0.59 | 0.45 | +176.47% |
| 2023-02-06 | 0.13 | -0.39 | -389.12% |
| 2022-11-28 | -0.54 | -0.81 | -48.84% |